Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypoglycaemia Was Not Associated With Depression, Anxiety, Diabetes Distress or Fear of Hypoglycaemia Scores in People With Type 1 or Insulin-Treated Type 2 Diabetes in the Hypo-METRICS Study.

Diabetes, obesity & metabolismยท2026
Same author

Gold and Clarke Questionnaires Identify Different People With Insulin-Treated Diabetes and Impaired Awareness of Hypoglycaemia in Almost 60% of Cases: A Post Hoc Analysis From the Hypo-METRICS Study.

Diabetes, obesity & metabolismยท2026
Same author

Exploring the gap between sensor-detected (SDH) and person-reported hypoglycaemia (PRH): The voice of people living with diabetes.

Diabetic medicine : a journal of the British Diabetic Associationยท2026
Same author

[Characteristics and methods of use of insulins].

La Revue du praticienยท2026
Same author

Diabetes community calls for quality standards for continuous glucose monitoring devices.

The Lancet regional health. Europeยท2026
Same author

Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel-group clinical trial sub-study.

Diabetes, obesity & metabolismยท2026
Same journal

From Dysbiosis to Diabetes: How Gut Microbiome Interventions Influence Type 2 Diabetes.

Current diabetes reviewsยท2026
Same journal

Innovative Phytochemical-Based Approaches for the Treatment of Diabetic Foot Ulcers.

Current diabetes reviewsยท2026
Same journal

Corrigendum to: Determination, Validation, and Development of Prediction Scores Related to Hypoglycemia Risk Factors Among Ambulatory Type 2 Diabetes Mellitus Patients in Bali, Indonesia.

Current diabetes reviewsยท2026
Same journal

Corrigendum to: The Potential of Ozone Therapy as an Adjunct to Periodontal Treatment in Diabetes Mellitus: A Biomarkers Scoping Review.

Current diabetes reviewsยท2026
Same journal

Integrative Nanotechnology and Biomaterial Approaches for Targeted Diabetic Wound Regeneration.

Current diabetes reviewsยท2026
Same journal

Characteristic Correlation between Staphylococcal Isolates from Wounds and Nares of Diabetic Foot Patients Living in Erbil City, Iraq.

Current diabetes reviewsยท2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2026

Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

Implantable continuous glucose sensors.

Eric Renard1

  • 1Endocrinology Department, Lapeyronie Hospital, F34295 Montpellier cedex 5, France. e-renard@chu-montpellier.fr

Current Diabetes Reviews
|August 12, 2008
PubMed
Summary
This summary is machine-generated.

Fully implantable glucose monitoring systems (IGMS) offer a promising alternative to current sensors, providing long-term glucose tracking. Despite biointerface challenges, IGMS show potential for improved diabetes management and closed-loop insulin delivery.

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Related Experiment Videos

Last Updated: Jul 2, 2026

Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Area of Science:

  • Biomedical Engineering
  • Medical Devices
  • Diabetes Technology

Background:

  • Wearable needle-type or microdialysis enzymatic sensors have limitations for clinical use.
  • Fully implantable glucose monitoring systems (IGMS) are a promising alternative with potential benefits like reduced invasiveness and less frequent calibration.
  • Pilot studies have provided initial data on subcutaneous and intravenous IGMS.

Purpose of the Study:

  • To evaluate the performance and longevity of fully implantable glucose monitoring systems (IGMS).
  • To identify challenges and benefits associated with subcutaneous and intravenous IGMS.
  • To assess the potential of IGMS for improving glucose control and closed-loop insulin delivery.

Main Methods:

  • Pilot studies involving subcutaneous and intravenous IGMS implantation.
  • Monitoring of sensor function, accuracy, and longevity.
  • Assessment of biointerface issues, including tissue reactions and sensor damage.
  • Evaluation of IGMS data for glucose range improvement and closed-loop control.

Main Results:

  • No severe adverse events were reported, but biointerface issues caused IGMS failures.
  • Subcutaneous IGMS functioned for an average of 120 days, while intravenous sensors lasted 259 days with satisfactory accuracy.
  • IGMS data improved time in normal glucose range for patients and enabled safe closed-loop glucose control.

Conclusions:

  • IGMS show a favorable perspective for long-term glucose monitoring and diabetes management.
  • Improvements in biointerface conditions are crucial for enhancing IGMS function and longevity.
  • Affordability and further development are key for widespread clinical adoption of IGMS.